NEW YORK (AP) -- Regeneron Pharmaceuticals Inc. says regulators approved marketing of its eye drug Eylea, an injection designed to treat a common cause of blindness in senior citizens.
Eylea is intended to treat "wet" age-related macular degeneration. More than 200,000 cases are diagnosed in the U.S. every year. The only other drug approved for the condition is Roche's Lucentis, which was approved in 2006 and posts $1.5 billion in annual sales.
A Food and Drug Administration advisory panel unanimously recommended approval for Eylea in June, but in August, the FDA extended its review of the drug by three months to review additional data.
If the drug is approved in other markets, Bayer HealthCare will market Eylea and the companies will split the profits.
KKTV firmly believes in freedom of speech for all and we are happy to provide this forum for the community to share opinions and facts. We ask that commenters keep it clean, keep it truthful, stay on topic and be responsible. Comments left here do not necessarily represent the viewpoint of KKTV 11 News.
If you believe that any of the comments on our site are inappropriate or offensive, please tell us by clicking “Report Abuse” and answering the questions that follow. We will review any reported comments promptly.powered by Disqus